Le Lézard
Classified in: Health
Subjects: CHI, SVY

Study confirms Neurofeedback has long-term benefit for Children with ADHD


ATLANTA, Feb. 20, 2018 /PRNewswire/ -- A study just published in the February issue of the medical journal European Child & Adolescent Psychiatry shows Neurofeedback to have long-term positive effects in children with ADHD.

 (PRNewsfoto/neuroCare Group)

Neurofeedback is a non-invasive therapy, which is used to train brain activity, visualizing EEG waves on a computer screen via electrodes. This has been shown to help reduce symptoms of ADHD in children, particularly inattention and hyperactivity. However, scientists have debated whether the reported effects are long-lasting and a viable alternative to prescribing children with medications.

In this latest study, researchers compiled data of more than 500 children with ADHD comparing the results of Neurofeedback, with medications and "non-active" (no treatment) conditions. To critically interpret the data, researchers with different views on Neurofeedback were selected to contribute to the study.

They found that Neurofeedback had sustainable effects in the longer term, with positive and significant effects observed after six months of treatment. Moreover, the findings show that the effects of Neurofeedback show a tendency to improve over time, with no ongoing therapy sessions needed after the initial program compared to the group, which was still taking medication at six-month follow-up.

Dr. Martijn Arns, one of the researchers of the study from Research Institute Brainclinics in The Netherlands, is confident that Neurofeedback is a viable therapy option for children with ADHD.

"This meta-analysis shows that after an average of six-month follow-up, neurofeedback has a similar efficacy compared to active treatments including medication, opening the option to use medication more for short-term symptom relief, and using neurofeedback to achieve more longer-term benefit in ADHD, with the added benefit of there being almost no side-effects," explained Dr. Arns.

These results relate to specific evidence-based Neurofeedback methodologies, (i.e., Slow Cortical Potentials Training, Sensorimotor Rhythm Training, and Theta/Beta Training) and cannot be generalized to all forms of Neurofeedback.

Is Neurofeedback the new Ritalin?
While psychostimulant medications such as 'Ritalin' have been commonly prescribed to children or adolescents diagnosed with ADHD, prior research has shown the effects of medications tend to decrease after two years of use and may induce various side effects such as anxiety, nausea and adverse effects on sleep.

Neurofeedback is a non-pharmacological approach, which in the last 10 years has gained more and more interest for its potential as an effective and short-term intervention, which is not found to have any severe side-effects and no side-effects typical with medications.

Dr. Mark Ryan, Consultant Psychiatrist at neuroCare Clinics in Sydney, sees first-hand the benefit of Neurofeedback for children and adults with ADHD but notes its potential as therapy isn't widely understood.

About NeuroCare Group
neuroCare Group operates mental healthcare clinics worldwide, specialized in the scientifically proven neuromodulation techniques of Neurofeedback and Transcranial Magnetic Stimulation (TMS Therapy) for a range of mental health disorders, including ADHD and Major Depression. Following proven applications of these technologies, neuroCare is part of a paradigm shift in personalized mental healthcare, moving away from a 'one-size-fits-all' approach reliant on pharmacology. Protocols adopted in neuroCare Clinics have been tested and developed for more than 15 years by leading neuroscientist and psychologist Dr. Martijn Arns. neuroCare has opened clinics in Germany, The Netherlands, the United States and Australia. For more information, please visit neurocaregroup.com.

Media Contact for U.S. Inquiries:

neuroCare Group America: Audra Wait
Wait & Co.
615.504.8812
[email protected]

SOURCE neuroCare Group


These press releases may also interest you

at 20:50
Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue was RMB63.5 million, the R&D investment was RMB372 million, the cash and cash equivalent at the end of 2023 was...

at 20:35
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company announced that the first patient in China has been dosed in the Phase 1b clinical study of the combination of InnoCare's novel SHP2 (Src Homology 2 domain containing...

at 19:30
Willow Biosciences Inc. ("Willow" or the "Company") , a leading biotechnology...

at 18:56
Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:...

at 18:30
Striking Teamsters at pharmaceutical giant Cencora (formerly known as AmerisourceBergen) rallied today outside the company's Sacramento distribution center. The 124 warehouse workers are members of Teamsters Local 150 and have been on strike since...

at 18:00
Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr. Jessica M. Konen's Lab at Emory University School of Medicine....



News published on and distributed by: